Department of Health

Receiving Officer 09:04 AM, Aug 31, 2023

August 31, 2023

Dear Grant Emmanuel,

Thank you for your request dated Aug 30, 2023 under Executive Order No. 2 (s. 2016) on Freedom of Information in the Executive Branch, for Guidelines in Interpreting List of MDRP Products.

We received your request on Aug 30, 2023 and will respond on or before Sep 20, 2023 11:44:34 AM, in accordance with the Executive Order's implementing rules and regulations.

Should you have any questions regarding your request, kindly contact me using the reply function on the eFOI portal at https://www.foi.gov.ph/requests/aglzfmVmb2ktcGhyHQsSB0NvbnRlbnQiEERPSC0wNzM1OTg2MDIxNTEM, for request with ticket number #DOH-073598602151.

Thank you.

Respectfully,

FOI Receiving Officer
FOI Officer

Maker 10:56 AM, Aug 31, 2023

Good day!

Please be informed that we have endorsed your request to Pharmaceutical Division (PD) for action. Kindly await for their response.

Thank you!

Maker 05:49 PM, Sep 23, 2023

September 23, 2023

Dear Grant Emmanuel Sarno,

Greetings!

Thank you for your request dated Aug 30, 2023 11:44:34 AM under Executive Order No. 2 (s. 2016) on Freedom of Information in the Executive Branch.

Your Request

You asked for Guidelines in Interpreting List of MDRP Products.

Response to Request

Your FOI request is approved. 

The MRP encompasses the imposition of maximum prices at all levels of the supply chain, including, but not limited to, the manufacturer's price, trader's price, distributor's price, wholesaler's price, and retailer's price. It was formerly called the Maximum Drug Retail Price (MDRP).

A Price regulation through MRP on certain drugs and medicines, selected based on the following criteria:
a)	Drugs that address the health priorities of the general public, especially those that account for the leading causes of morbidity and mortality;
b)	Drugs that have high price differentials /arbitrage compared to international prices;
c)	Drugs that have limited competition in terms of lack of generic counterparts or lack of market access to these products; and
d)		Drugs where the innovator product is the most expensive yet most prescribed and/or dispensed in the market.

Addressing your specific concerns:
1.	E.g., "Isosorbide Dinitrate" - If a drug contains only "Isosorbide", is the drug not covered by MRP? Yes, the product is not covered by the MRP.
2.	E.g., "Trandolapri1+Verapami1" - If a drug contains only "Trandolapril", is the drug not covered by MRP? Yes, the product is not covered by the MRP.
3.	E.g., "10 mg modified-release tablet" - If a drug does not contain "modified- release", is the drug not covered by MRP? Yes, the product is not covered by the MRP.


Kindly note that the MRP list as outlined in Executive Orders (EOs) 104 and 155, is specific to the generic name, strength, dosage, and form of medicines. We trust that this addresses your query.

Kindly accomplish the FOI Feedback form at the link
https://bit.ly/DOHFOIFeedbackForm

Thank you


Your right to request a review

If you are unhappy with this response to your FOI request, you may ask us to carry out an internal review of the response by writing to the Central Appeals and Review Committee, at foi@doh.gov.ph. Your review request should explain why you are dissatisfied with this response, and should be made within 15 calendar days from the date when you received this letter. We will complete the review and tell you the result within 30 calendar days from the date when we receive your review request.

If you are not satisfied with the result of the review, you then have the right to appeal to the Office of the President under Administrative Order No. 22 (s. 2011).

Thank you.

Respectfully,

FOI Decision Maker
FOI Receiving Officer